Galapagos NV's collaboration with GlaxoSmithKline has hit a roadblock. Late last week the Belgian biotech reported that its Big Pharma partner had hit the brakes on a Phase II study of GSK2586184 for lupus after a first look at the data failed to demonstrate a positive effect.
Belgium's Galapagos NV says that GlaxoSmithKline is prepping a Phase II study of GSK2586184 (formerly GLPG0778)--its JAK1 inhibitor--for ulcerative colitis.
A day after AbbVie unveiled an $840 million tie-up to develop a new anti-inflammatory therapy, the pharma company is continuing its deal spree today with a $405 million discovery pact on cystic fibrosis with Belgium's Galapagos.
The North Chicago, IL-based drug giant and Belgium's Galapagos have agreed to expand their collaboration on an oral JAK1 inhibitor to include Crohn's disease.
Swiss drug giant Roche has exited an alliance with Belgium-based biotech Galapagos focused on fibrosis discovery, leaving Galapagos hunting for another partner to hunt for compounds against fibrotic diseases.
The cash deal delivers AP214, in development to prevent acute kidney injury associated with major cardiac surgery.
Belgian biotech Galapagos has made progress in its alliance with the Janssen Pharmaceutica unit of healthcare giant Johnson & Johnson, revealing today that it has identified the first preclinical candidate in the collaboration.
Abbott ($ABT) today revealed that it is paying Belgian biotech Galapagos $150 million upfront to license in a promising oral treatment for rheumatoid arthritis.
In an almost completely back-ended research deal, Belgium's Galapagos will rev up its drug discovery engine in search of new cancer treatments for France's Servier. Working with some established
Galapagos has a shot at adding up to $35 million in added payments from cancer trendsetter Genentech in the third extension of their drug discovery pact. The two companies announced this morning that